U.S.-based holding company Johnson & Johnson has recently agreed to pay up to $6.3 million in a class-action lawsuit involving customer complaints over infant Tylenol. On its packaging, J&J claimed that infant Tylenol was uniquely formulated specifically for babies, when in reality it was found to be the same concentration as children’s Tylenol. Although the two Tylenols are alleged to be formulated exactly the same, J&J sold infant Tylenol for an increased price. J&J has denied any foul play and claims that infant Tylenol is sold with a syringe for safe dosing in infants.
The settlement will reimburse customers who purchased infant Tylenol between October 3, 2014 and January 6, 2020. With proof of purchase, class members can collect an unlimited amount of bottles and receive $2.15 per bottle in return. Without proof of purchase, customers can collect up to seven bottles for the same monetary return. The deadline to file a claim is April 13, 2020.